Conference Proceedings

Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO)

L Kappos, E-W Radue, G Comi, X Montalban, H Butzkueven, H Wiendl, G Giovannoni, Y Naegelin, T Sprenger, N Mueller-Lenke, F Dahlke, R Gottschalk, P von Rosenstiel, Y Zhang, D Tomic

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2013